missing translation for 'onlineSavingsMsg'
Learn More
Learn More
VISTA Monoclonal Antibody (MIH64), NovaFluor™ Yellow 730, eBioscience™, Invitrogen™
Rat Monoclonal Antibody
Marca: Invitrogen M035T02Y07
Este artículo no se puede devolver.
Vea la política de devoluciones
Descripción
VISTA (V-domain Ig containing suppressor of T-cell activation), also known as B7-H5 or PD-1H, is a product of the VSIR gene. Although VISTA bears sequence homology to PD-L1 it has a different expression pattern. In both mouse and humans, VISTA is expressed predominantly on hematopoietic cells with the highest densities on myeloid cells, and lower levels on T cells. It is usually absent on B cells. VISTA expressed by antigen presenting cells has been shown to directly suppress proliferation and cytokine production of CD4 and CD8 T cells, making it a target for cancer immunotherapy. The reported ligands of VISTA include CD28H, VSIG-3 and VSIG-8.
Especificaciones
| VISTA | |
| Monoclonal | |
| 0.1 mg/mL | |
| PBS with 0.09% sodium azide; pH 7.2 | |
| Q9D659 | |
| VSIR | |
| Affinity chromatography | |
| RUO | |
| 74048 | |
| 4° C, store in dark, DO NOT FREEZE! | |
| Liquid |
| Flow Cytometry | |
| MIH64 | |
| NovaFluor Yellow 730 | |
| VSIR | |
| 4632428N05Rik; B7H5; B7-H5; C10orf54; C1H10orf54; C28H10orf54; C4H10orf54; chromosome 10 open reading frame 54; DD1alpha; Death Domain1alpha; Dies1; differentiation of ESCs 1; GI24; PD-1H; PDCD1 homolog; PD-H1; platelet receptor Gi24; PP2135; RIKEN cDNA 4632428N05 gene; SISP1; sisp-1; Stress-induced secreted protein-1; UNQ730/PRO1412; V-domain Ig suppressor of T cell activation; VISTA; V-set domain-containing immunoregulatory receptor; V-set immunoregulatory receptor; VSIR; V-type immunoglobulin domain-containing suppressor of T-cell activation | |
| Rat | |
| 25 μg | |
| Primary | |
| Mouse | |
| Antibody | |
| IgG2a κ |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido